Sartorius Stedim Biotech (FR:DIM) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sartorius Stedim Biotech, amid a volatile market, reports a slight decline in sales revenue by 1.2% in constant currencies for H1 2024, adjusting its full-year guidance to prior-year levels. The company sees a decrease in underlying EBITDA by 6.8% and a more conservative outlook due to mixed industry demand and geopolitical uncertainties, despite a robust equity ratio and reduced net debt. They maintain positive long-term prospects for the life science and biopharmaceutical markets without altering their medium-term targets up to 2028.
For further insights into FR:DIM stock, check out TipRanks’ Stock Analysis page.